The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.
In addition to high antibody levels, factors including exposure to the human papillomavirus (HPV) and antibody avidity may be important and necessary to protect against infection.
For patients with oropharynx cancer, the rates of head and neck cancer mortality and competing mortality vary depending on HPV status.
From 2013 to 2018, there was an increase in the percentage of adults aged 18 to 26 years who received one or more doses or the recommended number of doses of HPV vaccine.
Only one in four patients with sinonasal squamous cell carcinoma is tested for human papillomavirus.
US women who have received one dose of HPV vaccine have similar protection as women who have received two or three doses.
Vaccinating women and men up to age 45 years for HPV is predicted to have high costs per QALY gained.
Mailing human papillomavirus (HPV) self-sampling test kits to underscreened women may increase cervical cancer screening uptake in healthcare systems in the United States.
Survey results reveal HPV vaccine delivery practices and experiences among pediatricians and family physicians.
